S Eswara Reddy rejoins as joint drug controller after Centre revokes suspension

After the Union government revoked his suspension on December 26, former Joint Drug Controller S Eswara Reddy has rejoined the apex drug regulatory body.

The Delhi High Court granted bail to both Reddy and Biocon’s associate vice-president Praveen Kumar.

According to the CBI, three people were arrested in June after they were allegedly bribed to waive off a clinical trial requirement for a diabetes drug developed by Biocon Biologicals. The company, a Biocon subsidiary, has denied the charges.

Reddy was arrested on June 21 for allegedly taking a bribe to waive off the phase-3 clinical trial of the Insulin Aspart injection of Biocon Biologics. On July 19, a CBI court in Delhi rejected his bail application and those of Biocon Biologics’ Associate Vice President L Praveen Kumar and three others.

Reddy alleged that the proceedings were “part of some larger conspiracy not to let him appear for the interview for the above post (DCGI) though despite (CBI) proceedings, no departmental enquiry has been instituted against him”.

He didn’t elaborate on the conspiracy or those who were part of it.

He also told the court that due to his “impeccable career and character”, he was appointed interim Drug Controller of India from February 2018 to August 2019 and was likely to be appointed as such.

Opposing the bail plea, the CBI said they caught Reddy while he was accepting Rs 4 lakh from Dinesh Dua, director at Synergy Network India Private Limited.

Related Posts

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

CHENNAI: The Madras High Court on Friday dismissed a petition seeking to quash a First Information Report (FIR) registered against Puducherry-based pharmaceutical entities accused of manufacturing and distributing counterfeit medicines…

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

Chhattisgarh: Riding on policy reforms that earned it the top rank among large states in NITI Aayog’s Investment Friendliness Index 2026 for Regulatory Ease and Institutional Environment, Chhattisgarh has received…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

Pharma companies in a flux over Trump’s 200% tariff move on generics

Pharma companies in a flux over Trump’s 200% tariff move on generics

Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’